We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Thrombotic Microangiopathy (TMA) is a rare condition that occurs when small blood vessels become blocked, leading to a reduction in blood flow and potential damage to organs. It is often associated with complications following haematopoietic stem cell transplants.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
